Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Estriol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 6/20 | 0.85 |
| ▸ | ESR2 known ✓ | Q92731 | 5/20 | 0.85 |
| ▸ | LMNA | P02545 | 3/20 | 0.85 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.85 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.85 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.85 |
| ▸ | NR3C1 | P04150 | 2/20 | 0.85 |
| ▸ | SHBG | P04278 | 2/20 | 0.85 |
| ▸ | PGR | P06401 | 2/20 | 0.85 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.85 |
| ▸ | AR | P10275 | 2/20 | 0.85 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.85 |
| ▸ | SNCA | P37840 | 2/20 | 0.85 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.85 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.85 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.85 |
| ▸ | UGT1A10 | Q9HAW8 | 1/20 | 0.85 |
| ▸ | STS | P08842 | 3/20 | 0.64 |
| ▸ | CA1 | P00915 | 1/20 | 0.64 |
| ▸ | CA2 | P00918 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estriol SCHEMBL10412523 | 0.96 | ESR1 (0.89) | ESR1ESR2LMNACYP2C9CYP2C19 | |
| Estriol SCHEMBL6438208 | 0.96 | ESR1 (0.89) | ESR1ESR2LMNACYP2C9CYP2C19 | |
| Estriol SCHEMBL7992695 | 0.95 | ESR1 (0.87) | ESR1ESR2LMNACYP2C9CYP2C19 | |
| Estriol SCHEMBL14373308 | 0.92 | ESR1 (1.00) | ESR1ESR2LMNACYP2C9CYP2C19 | |
| Epiestriol SCHEMBL221084 | 0.92 | ESR1 (1.00) | ESR1ESR2LMNACYP2C9CYP2C19 | |
| Estriol SCHEMBL23743979 | 0.92 | ESR1 (1.00) | ESR1ESR2LMNACYP2C9CYP2C19 | |
| Estriol SCHEMBL13123063 | 0.92 | ESR1 (1.00) | ESR1ESR2LMNACYP2C9CYP2C19 | |
| Estriol SCHEMBL2001122 | 0.92 | ESR1 (1.00) | ESR1ESR2LMNACYP2C9CYP2C19 | |
| Estriol SCHEMBL223196 | 0.92 | ESR1 (1.00) | ESR1ESR2LMNACYP2C9CYP2C19 | |
| Estriol SCHEMBL223226 | 0.92 | ESR1 (1.00) | ESR1ESR2LMNACYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9452175-B2 | Pregnancy hormone combination for treatment of autoimmune diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-09-27 | — | — | US | claimed |
| US-20160082017-A1 | ESTRIOL THERAPY FOR MULTIPLE SCLEROSIS AND OTHER AUTOIMMUNE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-03-24 | — | — | US | claimed |
| US-9168262-B2 | Estriol therapy for multiple sclerosis and other autoimmune diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-10-27 | — | — | US | claimed |
| EP-2698167-A2 | Dosage form of an estriol and glatiramer acetate polymer-1 for the treatment of multiple sclerosis | The Regents of The University of California (US) | 2014-02-19 | — | — | EP | claimed |
| US-20130280213-A1 | ESTRIOL THERAPY FOR MULTIPLE SCLEROSIS AND OTHER AUTOIMMUNE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2013-10-24 | — | — | US | claimed |
| US-20120322779-A9 | Estriol Therapy for Autoimmune and Neurodegenerative Diseases and Disorders | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-12-20 | — | — | US | claimed |
| US-20120014915-A9 | Estriol Therapy for Autoimmune and Neurodegenerative Disease and Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-01-19 | — | — | US | claimed |
| US-20090297477-A1 | Estriol Therapy for Autoimmune and Neurodegenerative Disease and Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-03 | — | — | US | claimed |
| US-20090131385-A1 | Estriol Therapy for Autoimmune and Neurodegenerative Diseases and Disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-05-21 | — | — | US | claimed |
| EP-1929291-A2 | ESTRIOL THERAPY FOR AUTOIMMUNE AND NEURODEGENERATAIVE DISEASES AND DISORDERS | The Regents of the University of California (US) | 2008-06-11 | — | — | EP | claimed |
| EP-1648406-A2 | USES AND FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION OF ACTIVE AGENTS | Antares Pharma IPL AG (CH) | 2006-04-26 | — | — | EP | claimed |
| US-20050239762-A1 | Estriol therapy for multiple sclerosis and other autoimmune diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2005-10-27 | — | — | US | claimed |
| EP-1100509-B1 | USE OF BIOGENIC ESTROGEN SULFAMATES FOR HORMONE REPLACEMENT THERAPY | SCHERING AG (DE) | 2005-04-06 | — | — | EP | claimed |
| EP-1397143-A4 | ESTRIOL THERAPY FOR MULTIPLE SCLEROSIS AND OTHER AUTOIMMUNE DISEASES | REGETNS OF THE UNIVERSITY OF C (US) | 2005-02-02 | — | — | EP | claimed |
| US-20040198706-A1 | Methods and formulations for transdermal or transmucosal application of active agents | ANTARES PHARMA, INC. | 2004-10-07 | — | — | US | claimed |
| WO-2004080413-A2 | USES AND FORMULATIONS FOR TRANSDERMAL OR TRANSMUCOSAL APPLICATION OF ACTIVE AGENTS | ANTARES PHARMA IPL AG (CH) | 2004-09-23 | — | — | WO | claimed |
| EP-1397143-A1 | ESTRIOL THERAPY FOR MULTIPLE SCLEROSIS AND OTHER AUTOIMMUNE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-03-17 | — | — | EP | claimed |
| US-20020183299-A1 | Estriol therapy for multiple sclerosis and other autoimmune diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2002-12-05 | — | — | US | claimed |
| WO-2002085374-A1 | ESTRIOL THERAPY FOR MULTIPLE SCLEROSIS AND OTHER AUTOIMMUNE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2002-10-31 | — | — | WO | claimed |
| CN-1311683-A | Use of biogenic estrogen sulfamates for hormone replacement therapy | JENAPHARM GMBH (DE) | 2001-09-05 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198706-A1 | Methods and formulations for transdermal or transmucosal application of active agents | SHBG, CYP17A1, NR5A1 | ESR1 249/4885ESR2 158/4885LMNA 3783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.